These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 22539486

  • 1. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.
    Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.
    Rheumatology (Oxford); 2012 Sep; 51(9):1670-6. PubMed ID: 22539486
    [Abstract] [Full Text] [Related]

  • 2. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
    Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.
    Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
    [Abstract] [Full Text] [Related]

  • 3. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
    Ohno I, Okabe H, Yamaguchi Y, Saikawa H, Uetake D, Hikita M, Gomi H, Ichida K, Hosoya T.
    Nihon Jinzo Gakkai Shi; 2008 Sep; 50(4):506-12. PubMed ID: 18546882
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.
    Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO.
    J Rheumatol; 2011 May; 38(5):904-10. PubMed ID: 21285173
    [Abstract] [Full Text] [Related]

  • 5. Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia.
    Stamp LK, Turner R, Khalilova IS, Zhang M, Drake J, Forbes LV, Kettle AJ.
    Rheumatology (Oxford); 2014 Nov; 53(11):1958-65. PubMed ID: 24899662
    [Abstract] [Full Text] [Related]

  • 6. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
    Panomvana D, Sripradit S, Angthararak S.
    J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
    [Abstract] [Full Text] [Related]

  • 7. An audit of a therapeutic drug monitoring service for allopurinol therapy.
    Kannangara DR, Ramasamy SN, Ray JE, Jones G, Graham GG, Williams KM, Day RO.
    Ther Drug Monit; 2013 Dec; 35(6):863-6. PubMed ID: 24263644
    [Abstract] [Full Text] [Related]

  • 8. Molecular mechanism of an adverse drug-drug interaction of allopurinol and furosemide in gout treatment.
    Knake C, Stamp L, Bahn A.
    Biochem Biophys Res Commun; 2014 Sep 12; 452(1):157-62. PubMed ID: 25152400
    [Abstract] [Full Text] [Related]

  • 9. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
    Stamp LK, Chapman PT, Barclay M, Horne A, Frampton C, Merriman TR, Wright DFB, Drake J, Dalbeth N.
    Clin Transl Sci; 2020 Jan 12; 13(1):110-115. PubMed ID: 31444839
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.
    Kankam M, Hall J, Gillen M, Yang X, Shen Z, Lee C, Liu S, Miner JN, Walker S, Clauson V, Wilson D, Nguyen M.
    J Clin Pharmacol; 2018 Sep 12; 58(9):1214-1222. PubMed ID: 29733447
    [Abstract] [Full Text] [Related]

  • 11. Individualising the dose of allopurinol in patients with gout.
    Kannangara DRW, Graham GG, Wright DFB, Stocker SL, Portek I, Pile KD, Barclay ML, Williams KM, Stamp LK, Day RO.
    Br J Clin Pharmacol; 2017 Sep 12; 83(9):2015-2026. PubMed ID: 28417592
    [Abstract] [Full Text] [Related]

  • 12. Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial.
    Stamp LK, O'Donnell JL, Frampton C, Drake JM, Zhang M, Chapman PT.
    Arthritis Rheum; 2013 Jun 12; 65(6):1636-42. PubMed ID: 23681955
    [Abstract] [Full Text] [Related]

  • 13. The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
    Stamp L, Gow P, Sharples K, Raill B.
    Aust N Z J Med; 2000 Oct 12; 30(5):567-72. PubMed ID: 11108066
    [Abstract] [Full Text] [Related]

  • 14. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
    Keith MP, Gilliland WR.
    Clin Pharmacol Ther; 2011 Sep 12; 90(3):363-4. PubMed ID: 21862966
    [Abstract] [Full Text] [Related]

  • 15. Predicting allopurinol response in patients with gout.
    Wright DF, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK.
    Br J Clin Pharmacol; 2016 Feb 12; 81(2):277-89. PubMed ID: 26451524
    [Abstract] [Full Text] [Related]

  • 16. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
    Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, Dalbeth N.
    Arthritis Rheum; 2012 Aug 12; 64(8):2529-36. PubMed ID: 22488501
    [Abstract] [Full Text] [Related]

  • 17. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
    Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT.
    Arthritis Rheum; 2011 Feb 12; 63(2):412-21. PubMed ID: 21279998
    [Abstract] [Full Text] [Related]

  • 18. A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis.
    Wright DF, Doogue MP, Barclay ML, Chapman PT, Cross NB, Irvine JH, Stamp LK.
    Eur J Clin Pharmacol; 2017 Jan 12; 73(1):71-78. PubMed ID: 27683090
    [Abstract] [Full Text] [Related]

  • 19. The impact of peritoneal dialysis on oxypurinol and urate elimination in people with gout.
    Wilson LC, Ward J, Wright DFB, Green SC, Stocker SL, Putt TL, Schollum JBW, Walker RJ.
    Nephrology (Carlton); 2024 Aug 12; 29(8):547-550. PubMed ID: 38626950
    [Abstract] [Full Text] [Related]

  • 20. Lack of effect of tart cherry concentrate dose on serum urate in people with gout.
    Stamp LK, Chapman P, Frampton C, Duffull SB, Drake J, Zhang Y, Neogi T.
    Rheumatology (Oxford); 2020 Sep 01; 59(9):2374-2380. PubMed ID: 31891407
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.